To enhance and prolong human life
CORPORATE FACTS

Location: Vancouver, BC (UBC spin-off)

Founders: Geoffrey Hoffmann and George Hoffmann


Lead Product: Preventive Drug for Inflammatory Disease

Team: 5 Directors, 4 Scientific Advisory, 3 Management

Financing Raised to Date: $1.1M

Seeking: $4M for pre-clinical toxicology and Phase I Trial to optimal Exit
### PIPELINE AND EXIT

<table>
<thead>
<tr>
<th>Stage</th>
<th>Discovery</th>
<th>Pre-Clinical</th>
<th>Phase I</th>
<th>Phase II</th>
<th>Phase III</th>
<th>Approval</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inflammation Preventive Drug</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pre-transplant Drug</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cancer Preventive Drug</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

License and Exit with Big Pharma
NETWORK IMMUNOLOGY

PRODUCT

TEAM

OPPORTUNITY
PRODUCT
We have the technology to combine two immune systems, to create a stronger immune system.

Implications:
- For Inflammatory diseases
  → Fundamentally strengthen your immune system
HISTORY OF IMMUNE NETWORK THEORY

Dr. Niels Jerne
Immune Network Hypothesis; Awarded Nobel Prize in 1984

Dr. Geoffrey W. Hoffmann
Developed Immune Network Theory From 1974 to Present
Leading Authority of Theory Today
1974
Niels Jerne formulates immune network hypothesis

1984
Jerne wins Nobel Prize for immune network theory

1985
Immunologists are unable to resolve the IJ paradox (central to network theory), and they leave the network paradigm

1994
Hoffmann publishes a paper on principle of co-selection, with the resolution to the IJ paradox

2008
Hoffmann and Leung discover a new co-selection phenomenon

2014-2016
Data obtained supporting co-selection based technologies

2010
Extension of theory
MAIN PREMISE:
The immune system is composed of cells and antibodies that interact with one another as a network.

- Understanding these network interactions is critical to understanding the adaptive immune system.
- We are the only company worldwide developing technologies based on this understanding.
EXTERNAL VALIDATION OF PLATFORM

- IRAP Canada (Government Funding)

- PREVENT (Centre of Excellence)


We have discovered a fundamental principle of the immune system.
Proof of Principle

• Technology transformed immune systems of one group of mice to be compatible with those of another group of mice.
First Experiment: Prolonged Transplant Survival

→ Subtle perturbation of the immune system caused 100% enhancement of skin graft survival time to day 30 without the use of immunosuppressant drugs.
Second Experiment: Further Extended Transplant Survival

Increase of approx. 200% duration of skin graft survival in treated (△) versus control (●) was observed.

Note: Skin graft transplanted into mice with same genetic background showed no rejection (▲)
SUMMARY OF KEY DATA

• First experiment – 100% enhancement of skin graft survival time without immunosuppressant drugs
• Second experiment – 200% enhancement of skin graft survival time without immunosuppressant drugs
• No loss of self tolerance, no loss of ability to respond to third party tissue
• Design of experiment based on the symmetrical immune network theory
UNIQUE METHOD OF ACTION

• This method does not involve suppressing the immune system

• Immune system plays a positive and active role in the technology

• Expected to remove need for harmful immunosuppressant drugs
IMPLICATIONS OF THE DATA

Transplantation

Autoimmunity

Degenerative Diseases

Cancer
• Technology tested in mouse model for prevention of inflammatory bowel disease (IBD)
• Mice treated with anti-anti-C3H plus anti-C3H IgG antibodies
• Therapy worked as measured in three different ways in DSS (dextran sodium sulphate) model:
  1. Reduced production of inflammatory cytokines
  2. Reduction in decrease of colon length
  3. Reduction in weight loss
IBD: PRODUCTION OF CYTOKINES

- **Left**: Control, no DSS
- **Middle**: DSS, high fat
- **Right**: DSS, high fat with anti-anti-C3H IgG plus anti-C3H IgG

Legend:
- TNFα
- IFNγ
- TGFβ
- IL-13
- IL-22
- IL-23
- IL-17
- IL-10
- CCR4

Graph showing mRNA levels for different cytokines under various conditions.
Effect of (anti-anti-C3H+anti-C3H) on colon length in mice with high fat diet treated with DSS.
Attenuation of body weight loss in BL/6 on high fat diet treated with DSS+ (anti-C3H+anti-anti-C3H)Ig

Control mice: No DSS
High fat: control Ig
High fat: anti-anti-Ig

Days post first DSS treatment (x5d)

Mean body weight/group (g)
Autoimmunity drug to be developed is a combination of two monoclonal antibodies

- Immune system stabilizer
- Preventive therapy
- Applicable to many inflammatory/autoimmune diseases
- Our blockbuster drug
TIMELINE AND MILESTONES

**Years 1 & 2**
- Preclinical PoC
- mAb production
- Nonclinical tox
- Preparation for IND

**Year 3**
- Licensing & Acquisition: $40M to $500M

**Year 4**
- 5X-10X Potential Exit
- Phase II
- Comparable Deals: $500M to $700M
$580MM - Roche and Adheron (October 9, 2015)

- $105 million up front; up to $475 million in milestones
- Deal done between Phase I and II.


$690MM - Lilly and Hanmi (March 19, 2015)

- $50 million up front; up to $640 million in milestones
- Deal done between Phase I and II


$544MM - Biogen and Mitsubishi Tanabe (September 9, 2015)

- $60 million in cash; up to $484 million in milestones
- Deal done between Phase II and III


Remicade: $10B in sales (2014)

- Both Humira and Remicade treat Ulcerative Colitis and other Autoimmune/Inflammatory diseases, including Psoriasis and Arthritis
- Both block one inflammatory cytokine (TNFa)
- NII’s drug, used as a preventive, reduced the production of seven key inflammatory cytokines, including TNFa
Immunosuppressant drug side effects:

- Infections due to suppressed immune system
- Increased susceptibility to cancer
- Liver and kidney damage
1) Produce drug (monoclonal antibodies)

2) Generate high impact pre-clinical (mouse) data for additional inflammatory diseases

2) Discussions with Pharma
TEAM
MANAGEMENT

George Hoffmann BA
Managing Director
Capital Raising, Business Development, Internal Administration

Edwin Gershom PhD
Chief Executive Officer
Business Development and Technology Commercialization, Experience in preclinical and clinical development projects

Geoffrey Hoffmann PhD
Chief Scientist and Chairman of Board of Directors
Managed laboratory at University of British Columbia for 20 Years; 40 years of theoretical and experimental immunology; Leading developer of Immune Network Theory
George Hoffmann BA  
Managing Director  
Built NII from idea stage, to a company with data for an revolutionary immuno-modulatory product

Daniel Wattier BSc.  
Completed one of BC’s most lucrative biotech exits for investors with sale of Valocor Therapeutics to Dermira in 2011;  
Contributes in the area of strategic direction

Jonathan Willmer MD  
Senior Medical Director, Global Research and Early Development at EMD Serono, formerly Merck Serono; past role as Chief Medical Director at CANTEST Clinical Research, Prime Trials Inc., CroMedica Inc.

John Hatton PhD  
PhD Oxford  
Physical Chemistry  
As one of the company’s longest term directors, Dr. Hatton has been a consistent support for the company
SCIENTIFIC ADVISORY BOARD

Michael Grant PhD
Immunologist, Professor
Memorial University
Expertise in Immune Network Theory

Earnest Leung MSc
Experimentalist
Performed important work in Immune Network R&D

Rob Forsyth PhD
Lecturer in Biotechnology
BCIT
Experience with Immune Network Theory

Matt Parsons PhD
Immunologist
University of Melbourne
Expertise in Immune Networks
LEAN BUSINESS MODEL

- Tightly managed costs
- Low R&D costs
- No leased office or lab space
  → Studies contracted to reputable laboratories
  → Collaborators at five universities
- Efficient use of consultants
- Multiple highly experienced, non-paid advisors
INTELLECTUAL PROPERTY

• Patent portfolio includes:
  – Novel platform technology for immune system modification
  – Novel method of vaccination (flu, hepatitis, malaria)

• Technologies protected by 6 patent applications

• No known “freedom to operate” issues

• No known competitors working on immune network framework based technologies
PLAN AND EXIT

• Generate further high impact pre-clinical data during 2016-2017

• Develop towards clinical Phase I

• When at IND stage (2018 expected) sell company to Pharma and/or launch IPO
Financing Plan

Equity Financing

$4,000,000 for 10,000,000 shares at $0.40

Represents 27% of the company
<table>
<thead>
<tr>
<th>Category</th>
<th>Quantity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Current shares issued and outstanding</td>
<td>22,014,195</td>
</tr>
<tr>
<td>Current options outstanding</td>
<td>1,716,532</td>
</tr>
<tr>
<td>Warrants outstanding</td>
<td>3,300,000</td>
</tr>
<tr>
<td>Total shares, options, warrants pre-financing</td>
<td>27,005,727</td>
</tr>
<tr>
<td>New shares, $4,000,000 financing at $0.40</td>
<td>10,000,000</td>
</tr>
<tr>
<td>Total shares, options, warrants post-financing</td>
<td>37,005,727</td>
</tr>
</tbody>
</table>
• Inflammation preventive therapy with strong IP
• Excellent pre-clinical data in mice studies
• Multi-billion dollar markets
George Hoffmann
Managing Director
778-847-7521
george@networkimmunologyinc.com

Edwin Gershom
Chief Executive Officer
778-318-2607
edwin@networkimmunology.com

Network Immunology Inc.
3311 Quesnel Drive
Vancouver, BC
Canada V6S 1Z7
www.networkimmunology.com